{"id":"NCT02006706","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy","officialTitle":"An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08-10","primaryCompletion":"2007-11-23","completion":"2007-11-23","firstPosted":"2013-12-10","resultsPosted":"2014-11-06","lastUpdate":"2017-08-21"},"enrollment":15,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"rituximab [MabThera/Rituxan]","otherNames":[]},{"type":"DRUG","name":"methotrexate","otherNames":[]},{"type":"DRUG","name":"methylprednisolone","otherNames":[]}],"arms":[{"label":"MabThera/Rituxan","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of MabThera/Rituxan plus methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to at least 1 DMARD treatment. All patients will receive MabThera (1000mg iv infusion) on days 1 and 15, and methotrexate (10-25mg po) weekly. The anticipated time on study treatment is 3-12 months.","primaryOutcome":{"measure":"Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Rituximab/Methylprednisolone/MTX","deltaMin":2.98,"sd":1.8}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":3,"countries":["Serbia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":14},"commonTop":[]}}